Contact:Yuliya Havaleshko
Phone:(434)243-9900
E-mail:yih8f@virginia.edu
UVa Health System seeks adults with Glioblastoma for research study
Glioblastoma multiforme (GBM) is a type of malignant brain tumor. The usual treatments include surgery, radiation therapy, and chemotherapy. Unfortunately, these tumors are very difficult to treat and often recur within several months of treatment. GBMs are the second leading cause of death from cancers in people under the age of 35 and the fourth leading cause under the age of 54. There is no known cure for recurrent glioblastomas, and no available therapies have been proven to prolong survival by more than two months on average.
The purpose of this study is assess tumor control and survival in patients treated with an investigational medicine called XL184. Participants will undergo routine history and physical exam, tumor evaluations with magnetic resonance imaging (MRI), and routine blood tests.
You may qualify for the study if you:
" Are a male or non-pregnant female age 18 or older
" Have glioblastoma at first or second recurrence.
" Have evidence of tumor progression by MRI after completing radiation and chemotherapy
" Have completed radiation therapy 90 days or more before study enrollment.
" Had no more than two prior chemotherapy regimens for your tumor
" Are willing to practice effective method of birth control during study participation
You may not qualify for this study if you have/had/are:
" Other active cancers requiring therapy to control disease
" Receiving any other investigational agents
" Received more than two prior systemic antitumor therapies, including initial treatment for GBM and treatment for one prior relapse
" Unstable systemic disease, including active infection, uncontrolled
hypertension, or serious cardiac arrhythmia requiring medication
" Pregnant women or nursing women
You will not receive payment for participating in this study. Study drug will be provided by Exelixis, Inc.
For more information or to see if you qualify, please contact:
Contact: Yuliya Havaleshko
Phone: (434) 243-9900
Email: yih8f@virginia.edu
Primary Investigator: David Schiff, MD Accepts adult enrollment: YES
IRB-HSR# 14185
|
|
Primary Investigator: Schiff David,